Cost-Effectiveness of a Potential Vaccine for Coccidioides immitis
Author Information
Author(s): Amber E. Barnato, Gillian D. Sanders, Douglas K. Owens
Primary Institution: University of Pittsburgh
Hypothesis
Is a potential vaccine against Coccidioides immitis cost-effective for preventing coccidioidomycosis?
Conclusion
Vaccination of children in highly endemic regions would provide a larger health benefit and reduce total health care expenditures.
Supporting Evidence
- Vaccination would save 1.9 quality-adjusted life days (QALD) and $33 per child.
- Screening followed by vaccination for adults would cost $62,000 per quality-adjusted life year (QALY) gained.
- Immunizing the birth cohort in endemic counties could avert 11 deaths and save $3 million.
Takeaway
The study looks at whether a vaccine for a fungal infection called coccidioidomycosis is worth the money. It finds that vaccinating kids in areas where the disease is common can save lives and money.
Methodology
A decision model was used to evaluate the health and economic consequences of different vaccination strategies.
Potential Biases
The study did not model race independently or exposure risk, which may affect the results.
Limitations
The model may not accurately represent the general population due to changes in ecology and demographics since earlier studies.
Participant Demographics
Children (average age 8.85 years, 14.5% naturally immune) and adults (average age 39.51 years, 47.5% naturally immune) from highly endemic regions.
Want to read the original?
Access the complete publication on the publisher's website